NASDAQ:KPTI - Karyopharm Therapeutics Stock Price, Forecast & News

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Karyopharm Therapeutics Inc (NASDAQ:KPTI) posted its quarterly earnings results on Monday, November, 4th. The company reported ($0.67) EPS for the quarter, beating the Zacks' consensus estimate of ($0.84) by $0.17. The company earned $13.15 million during the quarter, compared to analyst estimates of $1.61 million. Karyopharm Therapeutics had a negative net margin of 909.24% and a negative return on equity of 187.25%. View Karyopharm Therapeutics' Earnings History.

Karyopharm Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Karyopharm Therapeutics.

6 brokers have issued 1-year target prices for Karyopharm Therapeutics' stock. Their forecasts range from $5.00 to $37.00. On average, they anticipate Karyopharm Therapeutics' share price to reach $22.33 in the next twelve months. This suggests a possible upside of 31.6% from the stock's current price. View Analyst Price Targets for Karyopharm Therapeutics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Karyopharm Therapeutics.

Media stories about KPTI stock have trended positive this week, InfoTrie reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Karyopharm Therapeutics earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Karyopharm Therapeutics.

Karyopharm Therapeutics saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 9,570,000 shares, a decrease of 6.8% from the December 15th total of 10,270,000 shares. Based on an average daily trading volume, of 1,260,000 shares, the short-interest ratio is presently 7.6 days. Approximately 17.2% of the company's stock are sold short. View Karyopharm Therapeutics' Current Options Chain.

Some companies that are related to Karyopharm Therapeutics include United Therapeutics (UTHR), Allakos (ALLK), Nektar Therapeutics (NKTR), FibroGen (FGEN), Mirati Therapeutics (MRTX), SAGE Therapeutics (SAGE), GW Pharmaceuticals PLC- (GWPH), Deciphera Pharmaceuticals (DCPH), Ultragenyx Pharmaceutical (RARE), Blueprint Medicines (BPMC), PTC Therapeutics (PTCT), Zai Lab (ZLAB), Myokardia (MYOK), Taro Pharmaceutical Industries (TARO) and HUTCHISON CHINA/S (HCM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Bristol-Myers Squibb (BMY), Micron Technology (MU), Exelixis (EXEL), Alibaba Group (BABA), Caladrius Biosciences (CLBS), Amarin (AMRN), Celgene (CELG) and GW Pharmaceuticals PLC- (GWPH).

Karyopharm Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include California Public Employees Retirement System (0.49%), Private Capital Advisors Inc. (0.17%), Campbell & CO Investment Adviser LLC (0.06%), First Midwest Bank Trust Division (0.04%) and SG Americas Securities LLC (0.01%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Institutional Ownership Trends for Karyopharm Therapeutics.

KPTI stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division and Private Capital Advisors Inc.. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Insider Buying and Selling for Karyopharm Therapeutics.

KPTI stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Campbell & CO Investment Adviser LLC and SG Americas Securities LLC. View Insider Buying and Selling for Karyopharm Therapeutics.

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KPTI stock can currently be purchased for approximately $16.97.

Karyopharm Therapeutics has a market capitalization of $1.07 billion and generates $30.34 million in revenue each year. The company earns $-178,410,000.00 in net income (profit) each year or ($3.14) on an earnings per share basis. Karyopharm Therapeutics employs 332 workers across the globe.View Additional Information About Karyopharm Therapeutics.

The official website for Karyopharm Therapeutics is http://www.karyopharm.com/.

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]